Idorsia IDIA

SWX: IDIA | ISIN: CH0363463438 14:43

2,050 CHF (+13,26%)

(+13,26%) 14:43

Grafiek Idorsia Ltd

Grafiek Idorsia Ltd

1 dag1d 13,26%
1 week1w 17,68%
1 maand1m -13,79%
3 maanden3m 41,28%
6 maanden6m 11,23%
1 jaar1j -76,57%
5 jaar5j -89,79%

Idorsia Ltd in het nieuws

Toon enkel gratis nieuws

1 mei 2024 · Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond · Persbericht

26 april 2024 · JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension · Persbericht

23 april 2024 · Idorsia publishes an invitation to a bondholder meeting · Persbericht

17 april 2024 · Idorsia publishes a Financial Status required for an upcoming bondholder meeting · Persbericht

11 april 2024 · Idorsia takes steps to address short-term liquidity needs · Persbericht

22 maart 2024 · Idorsia thanks Guy Braunstein for his years of service as he retires · Persbericht

20 maart 2024 · US FDA approves Idorsia’s once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives · Persbericht

18 maart 2024 · Idorsia and Viatris successfully close the transaction for the global research and development collaboration · Persbericht

28 februari 2024 · Idorsia and Viatris enter into a significant global research and development collaboration · Persbericht

10 januari 2024 · Idorsia presents at the J.P. Morgan Healthcare Conference – Adapting Idorsia for sustainable value creation · Persbericht

Profiel Idorsia Ltd

CEO: Jean-Paul Clozel

Werknemers: 3

Aandelen Idorsia Ltd

Beurswaarde: 341,32 miljoen CHF

Effecten: 188,57 miljoen

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe